DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by binding specific ligands, strongly contributes to mediating the killing of tumor or virus-infected cells. DNAM-1 specifically recognizes PVR and Nectin-2 ligands that are expressed on some virus-infected cells and on a broad spectrum of tumor cells of both hematological and solid malignancies. So far, while NK cells engineered for different antigen chimeric receptors (CARs) or chimeric NKG2D receptor have been extensively tested in preclinical and clinical studies, the use of DNAM-1 chimeric receptor-engineered NK cells has been proposed only in our recent proof-of-concept study and deserves further development. The aim of this perspective study is to describe the rationale for using this novel tool as a new anti-cancer immunotherapy.

Cifaldi, L., Melaiu, O., Giovannoni, R., Benvenuto, M., Focaccetti, C., Nardozi, D., et al. (2023). DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. FRONTIERS IN IMMUNOLOGY, 14, 1197053 [10.3389/fimmu.2023.1197053].

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy

Cifaldi L.
;
Melaiu O.;Benvenuto M.;Focaccetti C.;Nardozi D.;Barillari G.;Bei R.
2023-06-01

Abstract

DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by binding specific ligands, strongly contributes to mediating the killing of tumor or virus-infected cells. DNAM-1 specifically recognizes PVR and Nectin-2 ligands that are expressed on some virus-infected cells and on a broad spectrum of tumor cells of both hematological and solid malignancies. So far, while NK cells engineered for different antigen chimeric receptors (CARs) or chimeric NKG2D receptor have been extensively tested in preclinical and clinical studies, the use of DNAM-1 chimeric receptor-engineered NK cells has been proposed only in our recent proof-of-concept study and deserves further development. The aim of this perspective study is to describe the rationale for using this novel tool as a new anti-cancer immunotherapy.
giu-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti non anonimi
Settore MED/04
English
CAR-NK cells
DNAM-1
NK cell engineering
NK cell-based immunotherapy
solid tumors
Cifaldi, L., Melaiu, O., Giovannoni, R., Benvenuto, M., Focaccetti, C., Nardozi, D., et al. (2023). DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. FRONTIERS IN IMMUNOLOGY, 14, 1197053 [10.3389/fimmu.2023.1197053].
Cifaldi, L; Melaiu, O; Giovannoni, R; Benvenuto, M; Focaccetti, C; Nardozi, D; Barillari, G; Bei, R
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/336524
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact